peripheral blood drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (13)
Papers in which this entity is mentioned.
- Whole-genome landscapes of 1,364 breast cancers. (2026)
- Three-dimensional genome landscape of primary human cancers. (2025)
- Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. (2022)
- A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. (2021)
- Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
- Determining cell type abundance and expression from bulk tissues with digital cytometry. (2019)
- Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. (2019)
- Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. (2018)
- Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. (2018)
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. (2014)
- Clinical whole-exome sequencing for the diagnosis of mendelian disorders. (2013)
- ACMG clinical laboratory standards for next-generation sequencing. (2013)
- The Genotype-Tissue Expression (GTEx) project. (2013)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| peripheral blood | drug | 24 | 27 |
| peripheral blood | phenotype | 5 | 5 |